Huntington’s Disease

Rare Disease Report is proud to provide its readers with the most up-to-date news about Huntington's Disease.
Triple Threat: HD Patient Researches, Educates and Advocates
He’s a patient, an educator, and an advocate. Huntington's Disease patient and Bellingham researcher Jeff Carroll is a triple threat.
Ionis the completion of enrollment in its Phase 1/2a randomized, placebo-controlled, dose escalation study of IONIS-HTTRs in Huntington’s Disease patients.
On May 18, Pope Francis embraced 150 Huntington’s disease patients. The meeting was the first time a world leader recognized HD.
On Thursday, Pope Francis will become the first world leader to recognize the growing global burden that is Huntington’s Disease (HD).
The Papal audience will hopefully shine a spotlight on a disease that often remains hidden from the outside world.
The FDA has approved Austedo (deutetrabenazine) tablets for the treatment of chorea associated with Huntington’s disease. The drug has previously been referred to as SD-809 by its developers, Teva Pharmaceuticals.
Teva Pharmaceutical Industries announced that the FDA has accepted the resubmission of the New Drug Application (NDA) for SD-809 (deutetrabenazine) to treat chorea associated with Huntington disease (HD).
Teva Pharmaceutical’s treatment for Tardive Dyskinesia (TD) showed a statistically significant results in its Phase 3 trial.
VX15, a monoclonal antibody towards semaphorin 4D, is in a phase 2 clinical trial for the treatment of Huntington’s disease. The antibody has also been given orphan drug designation by the FDA.
$vacMongoViewPlus$ $vAR$